EXPERTS IN CANCER IMMUNOTHERAPY

WHO WE ARE

invIOs is a PRIVATE BIOTECH COMPANY based in Vienna, Austria, focusing on the discovery and development of next-generation cancer therapeutics.

We tailor I/O therapies against cancer indications with HIGH UNMET MEDICAL NEED.

We LAUNCHED IN 2022 as a spin-out of APEIRON Biologics.

Our team has deep and long-standing expertise across ALL LEVELS OF DEVELOPMENT in BIOTECH.

VISION AND MISSION

Our vision at invIOs is to transform patients’ lives with our SUSTAINABLE AND PROMISING TECHNOLOGIES.

Our mission is to become a LEADING GLOBAL BIOTECHNOLOGY COMPANY providing individualized treatments for patients.

Leadership Team

Peter Llewellyn-Davies

Chief Executive Officer, Chief Financial Officer (CEO/CFO)

More than 25 years of professional experience as Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc. as well as Advisory roles in companies to execute exit strategies. Peter is the founding president of BIOTECH AUSTRIA, the Austrian Biotechnology Association.

Romana Gugenberger

Chief Medical & Scientific Officer (CMSO)

Romana Gugenberger holds a PhD in Molecular Biology from the University of Vienna and worked several years at the Medical University of Vienna in the field of Cardiovascular Research and Tumor Biology. She joined APEIRON Biologics in 2010 supporting non-clinical and clinical projects. Currently she leads invIOs's APN401 clinical stage cell therapy project.

LEADERSHIP TEAM

Romana Gugenberger

Managing Director

Romana Gugenberger holds a PhD in Molecular Biology from the University of Vienna and possesses over two decades of experience in the field of tumor biology and immuno-oncology, coupled with more than fifteen years of experience in drug development and project management. She joined APEIRON Biologics in 2009, where she supported preclinical and clinical-stage projects. Since 2021, Romana has served on the management board of APEIRON Biologics and co-founded invIOs in 2022. After the sale of APEIRON in 2024, she is still on the management board of invIOs and currently serves as managing director.

Alexander Dohnal

Head of R&D, Extended Management Board

Alexander Dohnal holds a PhD in biochemistry from the Technical University Vienna, and has over 20 years of experience in tumor immunology and the development of small-molecule and cell-based therapies. He joined Apeiron Biologics, the parent company of invIOs, in 2017 and currently serves in senior R&D leadership roles. His career spans senior academic and industry management positions and is marked by substantial grant funding, patent authorship, and an extensive publication record in translational immuno-oncology and immune regulation.

Rainer Koch

Head of Finance, Extended Management Board

Rainer Koch, holds a M.A. in business from the University of applied sciences Wr. Neustadt with in depth Knowledge in Management accounting gained from University of Calofornia Los Angeles (UCLA). Rainer joined APEIRON Biologics in 2021 and successfully facilitated in his role as Part of the leadership team major corporate projects such as the demerger and the sale of APEIRON to an US investor. He gained his professional experience accross various industries such as Pharma, FMCG, Chemical and FinTech

SUPERVISORY BOARD

Manfred Reichl, PhD, JD, MSc

Chairman

Entrepreneur, investor, business angel ("Austrian Business Angel of the Year 2009"), and Senior Adviser to renowned global institutions (e.g. UBS Investment Bank, World Economic Forum). More than 20 years of experience in international strategic consulting as Senior Managing Partner at Roland Berger, heading Austria and Eastern Europe for more than 15 years. European Program Manager for a Computer Line at Hewlett Packard. Lecturer in Vienna respectively Munich on "Corporate Governance", "China", and "Globalization".

Ulrich Granzer, PhD

Board Member

Independent consultant with currently 40 employees focusing on global drug development and regulatory affairs with special considerations for orphan drugs. Ulrich Granzer has major experience with biotech products and small molecules including orphan products.
He holds a PhD in pharmaceutical chemistry. Prior to being independent he held senior positions at Glaxo, BASF pharma Knoll, and Bayer.
He has a track record of working on more than 300 new molecular entities (small molecules, proteins incl. antibodies, oligonucleotides, gene therapies, cell therapies).

Helmut Schuehsler, PhD

Board Member

Dr. Schuehsler led the creation of TVM Capital Healthcare in the United Arab Emirates in 2009, and in Singapore 2018, after he had joined the TVM Capital group of companies in Munich in 1990. Helmut has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health and life science market, and more than 50 IPOs and 30 M&A exit transactions.

SCIENTIFIC ADVISORS

Gottfried Baier

Professor Baier leads the Institute of Cell Genetics at the Medical University of Innsbruck's Department for Genetics and Pharmacology, where he also serves as Director of the Christian Doppler Laboratory for pharmacological cancer immunotherapy. His research achievements include the leading-edge discoveries of the central-staged PKC/Cbl-b and PKC/NR2F6 signaling pathways and their key role in the control of cancer immune surveillance. Professor Baier holds a PhD in medical microbiology and is the author of dozens of publications, reviews, abstracts and patents.

Thomas Bogenrieder

Professor Bogenrieder is Chief Medical Officer of Abbalos Therapeutics and an expert in clinical development of cancer immunotherapies. During a career spanning the private sector and academic research he has served as Group Leader Oncology at Boehringer Ingelheim in Vienna as well as Clinical Director Oncology at GSK's Oncology Center of Excellence. He holds a PhD from the University of Utrecht, an MD from Albert-Ludwigs-University in Freiburg, and is an Assistant Professor at the University of Tübingen.

Thorsten Füreder

Professor Füreder is a medical oncologist at the Medical University of Vienna. He is the program director for respiratory tract cancers (head and neck and lung cancer) and cancer of unknown primary at the Department of Medicine I, and serves as the chair of the immune-oncology tumor board. He has served as the principal investigator of several clinical Phase 1-3 trials and has published multiple international research articles. Professor Füreder holds an MD from the Medical University of Vienna and serves as president of the Austrian Head and Neck Cancer Society.

Supervisory Board

Manfred Reichl, PhD, JD, MSc

Chairman

Erwin Rasinger, MD

Austrian physician and politician. Studied Medicine and Business Administration in Vienna. Referee for ecology of the Medical Association of Austria. Member of Austrian National Assembly from 1994 until 2017.

Ulrich Granzer, PhD

Helmut Schuehsler, PhD

Edward D. Charles

A rounded finance professional, spending the first twenty years in banking where he was responsible for several derivatives trading books and then ran the European structured finance departments at J P Morgan, Credit Suisse and Bank of America. He has, in the last fifteen years, founded multiple financial businesses; including in the asset management, financial advisory and insurance underwriting arenas. For the last twenty years he has been a keen Private Equity investor in both the biotech and fintech industries and the Treasurer of Docklands Outreach, a London based charity. He holds a Masters from University College, Oxford in Politics, Philosophy and Economics and a Masters in Modern and Contemporary Literature from Birkbeck College, London.